Open Targets, a public-private partnership dedicated to pre-competitive drug discovery research, announced MSD (tradename of Merck & Co., Inc., Rahway, N.J., USA) as the latest partner to join the consortium, supporting Open Targets aim to accelerate the development of safe and effective medicines by leveraging cutting-edge technologies to identify, prioritize and validate potential drug targets.